Baxter Healthcare Limited - search results

triomel peripheral 4g/l nitrogen 700kcal/l with electrolytes, emulsion for infusion

baxter healthcare limited - calcium chloride dihydrate; phenylalanine; potassium chloride; histidine; arginine; aspartic acid; olive oil; alanine; threonine; tryptophan; tyrosine; valine; glucose monohydrate; glutamic acid; glycine; methionine; isoleucine; lysine; magnesium chloride hexahydrate; serine; proline; sodium acetate trihydrate; sodium glycerophosphate; soybean oil - emulsion for infusion - calcium chloride dihydrate; phenylalanine; potassium chloride; histidine; arginine; aspartic acid; olive oil; alanine; threonine; tryptophan; tyrosine; valine; glucose monohydrate; glutamic acid; glycine; methionine; isoleucine; lysine; magnesium chloride hexahydrate; serine; proline; sodium acetate trihydrate; sodium glycerophosphate; soybean oil - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

triomel 5g/l nitrogen 990kcal/l with electrolytes, emulsion for infusion

baxter healthcare limited - calcium chloride dihydrate; phenylalanine; potassium chloride; histidine; arginine; aspartic acid; olive oil; threonine; tyrosine; valine; glucose monohydrate; glutamic acid; glycine; methionine; isoleucine; l-tryptophan; lysine; magnesium chloride hexahydrate; serine; proline; sodium acetate trihydrate; sodium glycerophosphate; soybean oil - emulsion for infusion - calcium chloride dihydrate; phenylalanine; potassium chloride; histidine; arginine; aspartic acid; olive oil; threonine; tyrosine; valine; glucose monohydrate; glutamic acid; glycine; methionine; isoleucine; l-tryptophan; lysine; magnesium chloride hexahydrate; serine; proline; sodium acetate trihydrate; sodium glycerophosphate; soybean oil - blood substitutes and perfusion solutions - triomel peripheral is indicated for parenteral nutrition for adults and children greater than 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

Malta - English - Medicines Authority

triomel 7g/l nitrogen 1140kcal/l with electrolytes, emulsion for infusion

Malta - English - Medicines Authority

triomel 7g/l nitrogen 1140kcal/l, emulsion for infusion

baxter healthcare limited - phenylalanine; histidine; arginine; aspartic acid; olive oil; alanine; threonine; tyrosine; valine; glucose monohydrate; glutamic acid; glycine; methionine; isoleucine; l-tryptophan; lysine; serine; leucine; proline; soybean oil - emulsion for infusion - phenylalanine; histidine; arginine; aspartic acid; olive oil; alanine; threonine; tyrosine; valine; glucose monohydrate; glutamic acid; glycine; methionine; isoleucine; l-tryptophan; lysine; serine; leucine; proline; soybean oil - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

triomel 9g/l nitrogen 1070kcal/l with electrolytes, emulsion for infusion

Malta - English - Medicines Authority

triomel 9g/l nitrogen 1070kcal/l, emulsion for infusion

baxter healthcare limited - phenylalanine; histidine; arginine; aspartic acid; olive oil; alanine; threonine; tyrosine; valine; glucose monohydrate; glutamic acid; glycine; methionine; isoleucine; l-tryptophan; lysine; serine; leucine; proline; soybean oil - emulsion for infusion - phenylalanine; histidine; arginine; aspartic acid; olive oil; alanine; threonine; tyrosine; valine; glucose monohydrate 250 g; glutamic acid; glycine; methionine; isoleucine; l-tryptophan; lysine; serine; leucine; proline; soybean oil - blood substitutes and perfusion solutions

European Union - English - EMA (European Medicines Agency)

pemetrexed baxter

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).

Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac-baxter ketorolac trometamol 30 mg/1 ml solution for injection ampoule

baxter healthcare pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium hydroxide; hydrochloric acid; nitrogen; water for injections; sodium chloride - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac-baxter ketorolac trometamol 10 mg/1 ml solution for injection ampoule

baxter healthcare pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; ethanol; nitrogen; water for injections; hydrochloric acid; sodium hydroxide - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

furosemide-baxter furosemide (frusemide) 50 mg/5 ml solution for injection ampoule

baxter healthcare pty ltd - furosemide, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.